China’s AI drug research and development platform Galixir has secured nearly US$10 million in a Pre-A round financing co-led by Source Code Capital and DCM.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
